Centrinone-B

SKU: orb1707471

Description

Centrinone-B (LCR-323) is a potent and selective Plk4 inhibitor used in cancer research. It has demonstrated activity in cellular assays and is a key tool for investigating centriole duplication and potential therapeutic strategies, such as in triple-negative breast cancer models.

Research Area

Cell Biology

Key Properties

• CAS Number: 1798871-31-4
• MW: 631.67
• Purity: 98.71% (May vary between batches)
• Formula: C₂₇H₂₇F₂N₇O₅S₂
• SMILES: COc1c(Nc2cc(C)[nH]n2)nc(Sc2ccc(cc2F)S(=O)(=O)Cc2cccc(c2F)[N+]([O-])=O)nc1N1CCCCC1
• Target: PLK
• Solubility: H2O:< 0.1 mg/mL (insoluble);10% DMSO+90% Corn Oil:2 mg/mL (3.17 mM);DMSO:20 mg/mL (31.66 mM)

Bioactivity

• Target IC50:
  PLK4 (G95L):497.53 nM (Ki)|PLK4:0.59 nM (Ki)|Aurora B:5597.14 nM (Ki)|Aurora A:1239 nM (Ki)
• In Vitro:
  Centrinone-B (LCR-323) is a highly potent and selective PLK4 inhibitor that can reduce centrosomes without affecting Aurora A/B, and it induces apoptosis in most melanoma cell lines.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

LCR323, LCR-323, LCR 323, Centrinone-B, Centrinone B, CentrinoneB, Aurora B, Aurora A, Plk4, PLK4 G95L, PLK4

Compound Identifiers

PubChem CID

118704753